for carcinogenicity hazard assessment
Experts in mechanistic toxicity testing
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:
Genetic Toxicology
We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.
Developmental Toxicology
By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.
Mechanistic Toxicology
All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).
Happy Customers
We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:
"The differentiation between aneugens and clastogens is important in the hazard assessment of our pharmaceutical compounds. ToxTracker ACE conveniently combines the relevant endpoints to be able to do this"
“As a modern safety laboratory requiring mechanistic insights into mammalian toxicology, we adopted ToxTracker and installed the assay in-house. The expertise, training and support provided by Toxys for the technology transfer were excellent resulting in a seamless set-up of the assay in our facilities. In addition, we have had terrific reactivity from Giel and his team with our questions.”
"The ToxTracker assay is an excellent tool to evaluate the genotoxic potential of compounds, generating great additional value by dissecting the underlying genotoxic mechanisms, and thereby better assess the relevance of the genotoxic response in a fast and cost-efficient manner.”
“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”
"Orion has worked successfully with Toxys on a couple of occasions. We are happy with the open communication which makes planning the experiments and interpreting the results easy and straightforward. The assay is excellent follow-up for our in-house micronucleus test to reveal the mode-of-action and hence validate or in-validate the borderline positive/negative dilemma."
“A succesful genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”
"Mechanism-based screening assays like the ToxTracker can make a valuable contribution to the routine safety compliance screening of our products"
“The expertise at Toxys is clear when you discuss results. The proactive team works hard to generate results within the timelines"
The ReproTracker team wins the EPAA Science Prize 2022!
We are very proud that Dr Amer Jamalpoor, study director of ReproTracker and lead scientist in developmental toxicology, was awarded the EPAA European Partnership for Alternatives Science Prize 2022 for outstanding contributions towards animal-alternative testing methods. The awarded case study, “ReproTracker: an animal-free platform for developmental...
Toxys is scaling up in the US
After establishing a Toxys subsidiary in the US last year, we are scaling up our business at Toxys Inc. We have hired a Director of BD & Sales to expand our commercial activities and officially started the production of our ToxTracker kits and reagents in...
Our very first hands-on ToxTracker training!
Last week, we hosted our very first hands-on ToxTracker training together with ALTERTOX on the novel in vitro methods and AOP approaches in genetic toxicology. During the workshop, the participants received a hands-on experience with ToxTracker and learnt about the latest developments in genetic toxicology. We are thankful...
Search for the optimal genotoxicity assay for routine testing of chemicals: Sensitivity and specificity of conventional and new test systems
In the recent publication by Mišík et al. about New Approach Methods (NAMs) for genotoxicity testing, ToxTracker was highlighted as one of the NAMs. These NAMs are advantageous in that they provide insight into the mode-of-action of genotoxic substances. The authors concluded that promising alternatives to in vivo experiments could...
Testing the RangerPro herbicide with the ToxTracker assay for a mechanistic insight into the toxicity
In a recent publication by Mesnage et al, all the pesticide ingredients in the US glyphosate-based herbicides(GBHs) RangerPro were tested for toxicity. The ToxTracker assay identified the toxicity resulting from RangerPro exposure as multifactorial, involving ER stress caused by a polyoxyethylene tallow amine, POE-15, along with oxidative stress caused by glyphosate. Please click here to read the full...
Now offering DNA Repair-Profiler, the latest addition to our genetic toxicology assays
As of today, Toxys offers DNA Repair-Profiler, the latest addition to our genetic toxicology assays. DNA Repair-Profiler consists of a unique collection of mammalian cell lines, each with a deficiency in one of the major DNA repair pathways. The cell lines are applied to assess...
Webinar: Novel safety assessment of antiviral nucleoside analogues using ToxTracker
On the 30th of June, we hosted a webinar entitled "Novel safety assessment of antiviral nucleoside analogues using ToxTracker". During this webinar we shared the background, details and conclusions for the nucleoside analogues ToxTracker case study. Please click here to request the webinar from us. About ToxTracker ToxTracker...
Toxys is interviewed by Dutch news channel about the importance of animal-testing alternatives
April 24th commemorated the World Day for Animals in Laboratories. Our CEO, Giel Hendriks, was interviewed by RTL Nieuws (Dutch national news channel) to discuss the importance of animal-testing alternatives. At Toxys, we are focused on developing assays that provide a better understanding of toxicity without...
ReproTracker Webinar: ReproTracker as an in vitro alternative to animal models for developmental toxicity testing
On the 10th of March, we hosted a webinar on ReproTracker as an in vitro alternative to animal models for developmental toxicity testing. During the webinar, the technical validation of the ReproTracker assay and the case studies with applications of the assay were presented. Please click...
Toxys opens US office and production facility to accelerate growth
Oegstgeest, The Netherlands. March 16, 2022 - Toxys BV, a Dutch biotech company that offers a broad spectrum of innovative in vitro toxicology solutions for the safety assessment of novel medicines, (agro)chemicals, cosmetics, and food ingredients, today announces the opening of a sales office in...
